By Fineline Cube IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) — a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company’s proprietary targeted protein degradation platform.
Research Milestone
| Item | Detail |
|---|---|
| Company | IMPACT Therapeutics, Inc. (HKG: 7630) |
| Event | Nomination of preclinical candidate (PCC) |
| Candidate | IMP2794 |
| Modality | PROTAC (Proteolysis Targeting Chimera) |
| Target | KAT6A (highly specific) |
| Selectivity | Over 1,000-fold selectivity versus KAT6B |
| Platform | IMPACT Therapeutics’ proprietary targeted protein degradation platform |
| Announcement Date | 13 Aug 2026 |
| Milestone Significance | First PCC generated from the platform |
Preclinical Profile – IMP2794
- Potency & Selectivity: A potent and selective KAT6A degrader with over 1,000-fold selectivity against KAT6B — a critical distinction, as inhibition of KAT6B is associated with potential hematopoietic toxicities
- In Vitro: Displays potent cytotoxic activity against tumor cells with minimal hematopoietic toxicity
- In Vivo: Demonstrates significant antitumor efficacy in breast cancer CDX models
- Pharmacokinetics: Achieves remarkably high oral bioavailability across multiple animal species, indicating strong potential for optimal human systemic exposure
Target Rationale – KAT6A
- Expression: KAT6A is highly expressed in various cancers, particularly in estrogen receptor-positive (ER+) breast cancer
- Selectivity Challenge: Traditional small-molecule inhibitors struggle to achieve selective KAT6A targeting because of the homolog KAT6B, whose inhibition carries hematopoietic toxicity risk
- PROTAC Advantage: Molecules such as IMP2794 enable selective and tunable degradation of previously “undruggable” targets, broadening the therapeutic window and reducing toxicity
Market Impact & Outlook
- Platform Validation: IMP2794 is the first PCC from IMPACT Therapeutics’ TPD platform, validating the company’s degrader discovery engine and establishing a template for subsequent programs.
- Undruggable Target Opportunity: The nomination adds IMPACT Therapeutics to the growing cohort of companies pursuing PROTACs against targets that resist conventional inhibition, one of drug discovery’s most active frontiers.
- ER+ Breast Cancer Focus: With KAT6A highly expressed in ER+ breast cancer, the candidate is positioned against a large, commercially established oncology segment.
- Next Steps: IND-enabling studies and timelines toward first-in-human trials were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the preclinical development potential of IMP2794. Actual results may differ due to risks including IND-enabling progress, toxicology outcomes, and competitive dynamics in targeted protein degradation.-Fineline Info & Tech